COMING IN OCTOBER
Please check back for updates on when Beyfortus (nirsevimab) will be available in our office.
RSV, respiratory syncytial virus, is a respiratory illness that causes cold like symptoms in children and adults. It however, is the leading cause of hospitalization in children and infants under the age of 5. Beyfortus (nirsevimab) is a new RSV shot that will be available this fall for all infants entering their first RSV season that are under 8 months of age.
Beyfortus (nirsevimab) is NOT a vaccine. A vaccine stimulates the body to MAKE antibodies that help prevent the infection or disease process. Beyfortus (nirsevimab) is monoclonal antibody shot providing RSV antibodies directly to the body. These antibodies help provide immediate protection but wane over time. In this case, the shot lasts for the duration of the predicted RSV season which is usually late fall to early spring, approximately 5 months.
Beyfortus (nirsevimab) has been shown to prevent hospitalization and severe disease in 80% of infants receiving it. It does not prevent RSV but lessens the expectant severity of the illness in most cases. Side effects reported have been soreness at the injection site and rash. It is safe to administer with all other childhood vaccines.
It is recommended for all babies 8 months and younger as well as those infants aged 8 months to 19 months with certain underlying high risk conditions such as prematurity, congenital heart and lung conditions, and weakened immune systems.
Talk to your provider today to see if your child is eligible to receive this exciting new therapy!
Dr. Carole Anderson
Pediatrician at The Youth Clinic
Note: Due to the recent introduction of Beyfortus (nirsevimab), insurance carriers may not provide coverage for this medication. Families who elect to receive Beyfortus (nirsevimab) will be asked to sign an Advanced Beneficiary Notice (Insurance waiver) in the event insurance doesn’t cover this medication. We strongly encourage parents to contact their insurance to confirm if Beyfortus (nirsevimab) is covered.
